AskBio Advances Parkinson’s Gene Therapy With Commercial-Scale Manufacturing

In gene therapy, science gets the spotlight. But manufacturing decides whether that science actually reaches patients. AskBio Inc. just made a move that signals it’s thinking beyond the lab.

The Trigger: IND Amendment Clears Manufacturing Shift

Following an amendment to its Investigational New Drug (IND) application with the U.S. Food and Drug Administration, AskBio has introduced a commercially ready manufacturing process for:

• ametefgene parvec (AB-1005)
• An investigational gene therapy for Parkinson’s disease (PD) and Multiple system atrophy-parkinsonian type (MSA-P)

This isn’t just a process upgrade. It’s a shift toward scale, consistency, and regulatory readiness, before approval.

Why This Matters: Manufacturing Is the Bottleneck in Gene Therapy

AskBio is now supplying clinical trial material using:

• A next-generation, large-scale suspension manufacturing process
• Designed for high purity and consistency
• Built for commercial-level output, not just clinical batches

Translation: They’re solving one of gene therapy’s biggest problems early, how to scale without breaking quality.

The Engine Behind It: Viralgen

Production will be handled by Viralgen, AskBio’s specialized manufacturing arm. What Viralgen brings:

• Deep expertise in AAV (adeno-associated virus) platforms
• End-to-end capabilities, from development to commercial production
• Infrastructure already aligned with global regulatory expectations

This vertical integration gives AskBio a serious edge.

Clinical Progress: REGENERATE-PD Moves Forward

With manufacturing locked in, AskBio is advancing its REGENERATE-PD Phase II trial:

• First participants already randomized in Germany
• Ongoing enrollment in:
  • Poland
  • United Kingdom
  • United States

The trial:

• 127 participants (estimated)
• Ages 45–75
• Randomized, double-blind, surgery-controlled design

This is where manufacturing meets reality—consistent product, across multiple geographies.

What Leadership Is Signaling?

Canwen Jiang emphasized program momentum:

• Manufacturing platform is now actively supplying trial material
• Global enrollment is underway

Meanwhile, Christian Rommel highlighted the bigger picture:

• Manufacturing efficiency = mission critical
• Reflects both technical innovation and regulatory discipline

In gene therapy, those two rarely scale together. That’s the bet here.

Regulatory Tailwinds: Stacked Designations

AskBio isn’t building this in a vacuum. Regulators are already engaged. For Parkinson’s disease, ametefgene parvec has received:

• RMAT designation from the FDA
• Fast Track designation (FDA)
• Innovation Passport from the Medicines and Healthcare products Regulatory Agency
• SAKIGAKE designation in Japan

These aren’t trophies. They’re acceleration mechanisms.

Beyond Parkinson’s: MSA-P Also in Focus

AskBio is also evaluating the therapy in:

• A fully enrolled Phase I trial in the U.S.
• Targeting MSA-P, a rare and rapidly progressing condition

Key reality:

• ~400,000 patients globally
• No approved treatments
• Rapid decline within 5–10 years

High unmet need. High risk. High upside.

The Science: Why This Therapy Could Matter

Ametefgene parvec uses:

• An AAV vector to deliver the GDNF (glial cell line-derived neurotrophic factor) gene
• Direct neurosurgical delivery into the brain

The goal:

• Enable continuous GDNF expression
• Support survival of dopamine-producing neurons
• Potentially slow disease progression, not just manage symptoms

That’s the holy grail in Parkinson’s: disease modification, not symptom control.

The Bigger Picture: Bayer’s Long Game

AskBio operates independently but is fully owned by Bayer AG. This matters. Because scaling gene therapy requires:

• Capital
• Infrastructure
• Regulatory muscle

Bayer brings all three.

Final Take

Most companies wait until late-stage success to think about manufacturing. AskBio is doing the opposite:

• Build commercial-scale capability early
• De-risk clinical-to-commercial transition
• Align science with real-world delivery constraints

If the therapy works, they won’t be scrambling to scale. They’ll already be there.